Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 38.9% in July

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 16,792 shares, a drop of 38.9% from the July 15th total of 27,481 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 12,983 shares, the days-to-cover ratio is currently 1.3 days.

Institutional Trading of Pulmatrix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PULM. Dimensional Fund Advisors LP bought a new position in shares of Pulmatrix in the third quarter valued at approximately $52,000. DRW Securities LLC bought a new stake in Pulmatrix during the fourth quarter worth $46,000. Finally, BlackRock Inc. purchased a new stake in Pulmatrix in the 2nd quarter valued at $93,000. 11.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Pulmatrix Stock Down 0.8%

PULM stock traded down $0.01 during midday trading on Tuesday, reaching $1.55. 6,687 shares of the company’s stock traded hands, compared to its average volume of 42,460. The company has a market cap of $5.65 million, a price-to-earnings ratio of -1.39 and a beta of 1.91. The firm’s fifty day moving average price is $1.62 and its 200-day moving average price is $1.74. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $5.50.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $1.71.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).